1 / 12

Immunotherapy

Immunotherapy. Personal statistics John Weisnagel, M.D. Database . Sept 1992-June 2006: 23,577 patients Undergoing immunotherapy: 2,393 pts (10.14%) Perennial Rx (all-year long): 1,437 (60%)

taite
Download Presentation

Immunotherapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Immunotherapy Personal statistics John Weisnagel, M.D.

  2. Database • Sept 1992-June 2006: 23,577 patients • Undergoing immunotherapy: 2,393 pts (10.14%) • Perennial Rx (all-year long): 1,437 (60%) • Pre-seasonal Rx (one injection per week 1-2 months preceding the specific pollen season): 936 (39.1%) • 20 pts having rec’d both types of treatment.

  3. Efficacy of immunotherapy • Of the 2,393 treated since 1992, • 983 replied to the question of the effect of their treatment (excellent, very good, good, slight or no change) when reminders were sent them about renewals • Treatment was either: • Perennial or • Pre-seasonal.

  4. Perennial Treatment • 581 patients: • Asthma: 53 (9.12%) • Asthma + pollinosis: 74 (12.7%) • Asthma + rhinitis: 83 (14.2%) • Pollinosis: 148 (25.47%) • Rhinitis: 223 (38.38%)

  5. Efficacy of Perennial treatment in 581 patients

  6. Pre-seasonal Treatment • 402 patients: • Asthma + pollinosis: 6 (1.4%) • Asthma + rhinitis: 2 (0.49%) • Pollinosis: 393 (97.76%) • Rhinitis: 1 (0.29%)

  7. Efficacy of pre-seasonaltreatment in 402 patients

  8. Totals

  9. Efficacy summary

  10. Pre-seasonals • Center-Al™ • Suspal™ • Pollinex R™ • Other tyrosine preps.

  11. Perennials • Mixtures: • House dust mite + pollens • House dust mite + molds • House dust mite + pollens + molds

  12. Bottom line • These personal statistics, though anecdotal, reflect the conclusion of the many studies published on the benefit of immunotherapy. • Both forms of therapy, perennial and pre-seasonal have similar benefits. • Immunotherapy is still an effective treatment in respiratory allergy, and should be considered when pharmaceutical therapy is inadequate.

More Related